Pillar guide
Body Recomposition: The UK 2026 Editorial Guide to Lean-Mass Preservation on GLP-1 Medication and the Peptide-Research Lane
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Hero capsule
Body recomposition is the simultaneous loss of fat mass and preservation, or modest gain, of lean mass. It is not a fringe gym concept any more. In 2026 it has become one of the defining metabolic conversations in UK adult health, because the GLP-1 medication class has moved hundreds of thousands of people through rapid weight loss in eighteen months, and the published trial data is unambiguous that a meaningful fraction of the weight lost on these medications is lean tissue rather than fat. This editorial walks the current literature, the protein-threshold consensus for adults losing weight, the resistance-training evidence base, and the research-use-only peptide lane that intersects with body composition. It is informational. It is not clinical advice. Your prescriber decides.
What body recomposition means in clinical practice
In a clinical context, body recomposition is the change in the ratio of fat mass to fat-free mass over a defined window. Fat-free mass is mostly skeletal muscle, but also includes water, organ tissue, connective tissue, and the mineral fraction of bone. The most common measurement instrument in the published literature is dual-energy X-ray absorptiometry, abbreviated DXA, which produces a three-compartment estimate of fat mass, lean soft tissue, and bone mineral content. Bioelectrical impedance analysis is the cheaper consumer-grade alternative, but the trial evidence consistently relies on DXA because of its lower coefficient of variation in tracking modest soft-tissue changes over six to twelve months.
When a person loses weight from any cause, including caloric restriction, surgery, illness, or pharmacological appetite suppression, the weight lost is never one hundred per cent fat. The historical estimate, drawn from the dietary-restriction literature of the late twentieth century, is that roughly twenty to thirty per cent of total weight lost in unaccompanied caloric restriction is fat-free mass. Some of that is water, some is gut and organ tissue adapting to a smaller body, and a meaningful component is skeletal muscle. The clinical concern is not the loss of fat-free mass per se. It is what happens after the weight-loss phase ends. Fat tends to regain easily. Skeletal muscle, particularly in adults over forty-five and especially in adults over sixty, does not.
This is the sarcopenia concern. The European Working Group on Sarcopenia in Older People formalised the diagnostic criteria for clinically meaningful low muscle mass and low muscle strength in older adults, and the concern in 2026 is the demographic overlap. The cohort being prescribed GLP-1 medications in the UK skews towards adults in their forties, fifties and sixties. The cohort with the highest baseline risk of clinical sarcopenia is the same demographic window, especially on the older end. Rapid weight loss in this group, without lean-mass preservation strategies, increases the probability of crossing into measurable functional decline ten or fifteen years down the line. That is the substance of the clinical conversation right now.
The GLP-1 lean-mass evidence base
The two pivotal published trials are STEP-1 and SURMOUNT-1. STEP-1, reported by Wilding and colleagues in 2021 (PMID 33567185), randomised adults with overweight or obesity to a once-weekly GLP-1 receptor agonist or placebo. The headline finding was a mean weight reduction of around fourteen and a half per cent over sixty-eight weeks in the active arm, compared with two and a half per cent in placebo. The DXA substudy, which is the piece most relevant here, found that of the total weight lost, roughly forty per cent was fat-free mass. The proportion of fat-free mass to total mass actually rose slightly, because fat fell faster than lean, but the absolute kilograms of lean tissue lost was clinically substantial in older participants.
SURMOUNT-1, reported by Jastreboff and colleagues in 2022 (PMID 35658024), tested the dual GIP and GLP-1 receptor agonist class. The total weight loss was higher, around twenty to twenty-two per cent at the higher dose tier over seventy-two weeks. The DXA substudy reported a similar fat-to-lean loss ratio. Total lean-mass loss in absolute terms was therefore larger than STEP-1 simply because total weight loss was larger. The interpretive question, which the trial authors flagged in the discussion, is whether the absolute lean-mass loss exceeds what would be expected from any equivalent weight-loss intervention, or whether it tracks the historical bariatric-surgery comparators.
The Linge and colleagues 2024 reanalysis (PMID 38387458) is the most cited paper that addressed that question directly. Using MRI-based body composition rather than DXA, they reported that the lean-mass loss with GLP-1 receptor agonists was broadly consistent with what is seen in surgical and dietary weight loss of similar magnitude, and that the ratio of visceral-adipose-tissue loss to lean-mass loss was favourable. That paper is the strongest published case against the framing that GLP-1 medications uniquely strip muscle. The case for caution remains the absolute kilogram count in older adults, not the ratio.
The Conte and colleagues 2022 narrative review (PMID 36207314) summarised the broader concern about pharmacological weight loss and sarcopenia risk in older adults, drawing on the bariatric literature as well as the early GLP-1 data. The Wilding et al. 2022 extension paper (PMID 35441470) reported the post-treatment regain trajectory after STEP-1 was unblinded, and the regain was disproportionately fat rather than lean, which is the worst-case body-composition outcome.
Two further references frame the broader sarcopenic-obesity question in the UK and European context. Donini and colleagues 2022 (PMID 34553478) is the ESPEN and EASO consensus statement on the definition and diagnostic criteria for sarcopenic obesity, the condition of having both excess fat mass and clinically low muscle mass simultaneously, which is the population most relevant here. Prado and colleagues 2018 (PMID 30166099) is the canonical review on the role of body composition in cancer and chronic-disease prognosis, frequently cited because it links low muscle mass to worse functional and survival outcomes independently of body mass index.
The overall reading of the evidence base in 2026 is that GLP-1 medications produce body-composition changes that are not categorically different from other forms of large-magnitude weight loss, but the absolute scale and speed of weight reduction, combined with the demographic profile of the patient cohort, means lean-mass preservation strategies are a serious clinical and lifestyle question rather than a niche one. That is the consensus framing in current UK editorial coverage and in the published commentary from registered dietitians working in metabolic clinics.
The protein-threshold consensus
The single highest-confidence lever for lean-mass preservation during weight loss in adults is protein intake. This is one of the few areas in the nutrition literature where the trial and meta-analytic evidence broadly aligns. The PROT-AGE study group, reported by Bauer and colleagues 2013 (PMID 23764849), set the protein-per-kilogram-of-body-weight guidance for older adults losing weight at a level meaningfully higher than the general adult reference value. The European Society for Clinical Nutrition and Metabolism, ESPEN, position paper by Deutz and colleagues 2014 (PMID 24814383) confirmed and slightly refined that guidance, and added the recommendation that protein be distributed across meals to optimise muscle protein synthesis rather than loaded into one meal.
The mechanism is not contested. Skeletal muscle is in continuous turnover. Muscle protein synthesis is stimulated by feeding, particularly by feeding sufficient dietary leucine, and by mechanical loading. Muscle protein breakdown rises in caloric deficit. The simultaneous combination of higher protein intake and resistance loading is, in essence, the protocol the literature converges on for keeping the net balance positive enough to preserve lean mass even when overall energy balance is negative.
The published guidance for older adults losing weight is, in general framing, a higher protein intake per kilogram of body weight than the standard reference value used for sedentary younger adults. UK National Health Service general guidance, the British Dietetic Association, and the recent commentary from the British Nutrition Foundation on weight-loss medication, all converge on this point in 2026 editorial coverage, even where they differ on specifics. We are not going to publish a kilograms-per-day figure in this guide because the right number for any individual depends on baseline body weight, kidney function, lean-mass percentage, and prescriber assessment. The decision is between you and your prescriber, and the relevant calculation typically involves a registered dietitian rather than an editorial.
What we will say editorially is that the protein-threshold conversation is the single most evidence-supported lever in this entire body-recomposition discussion, and it is the one most under-discussed in UK consumer media around GLP-1 medication. The drug appetite-suppression effect makes hitting any meaningful protein intake structurally harder, because total food volume falls. Adults on GLP-1 medication frequently report eating less of everything, including protein, which is the worst-case body-composition outcome. Building meals around protein rather than carbohydrate, in the smaller total food volume that the medication imposes, is the practical implication that registered dietitians in the metabolic clinic literature consistently highlight.
Resistance training framing
The second lever, well-supported but with thinner GLP-1-specific trial data, is mechanical loading. The general adult resistance-training literature on lean-mass preservation during weight loss is unambiguous. Cermak and colleagues 2012 (PMID 22939366) is the canonical meta-analysis showing that resistance training combined with adequate protein intake produces meaningfully better lean-mass preservation outcomes during caloric restriction than caloric restriction alone. Morton and colleagues 2018 (PMID 28698222) refined that finding with a larger meta-analytic sample.
The honest framing on GLP-1-specific resistance-training trials is that we do not yet have a published gold-standard randomised trial of GLP-1 medication with versus without a structured resistance-training arm. The expectation in the field, drawing on the general weight-loss-and-resistance literature, is that the effect direction is the same and the magnitude is broadly comparable. We are not going to overstate that. The trial we want has not been published yet. The trial we have, in adjacent populations, points the same way.
Editorially, what this means is that resistance training during a GLP-1 weight-loss phase is the second most evidence-supported lever after protein intake, and that the two compound. Protein without loading is a partial intervention. Loading without protein is a partial intervention. The combined effect, in the general weight-loss literature, is the difference between losing a substantial fraction of weight as lean mass and losing the great majority as fat.
We will not prescribe a specific training programme. Frequency, intensity, modality and progression all sit in the territory of a chartered physiotherapist, a qualified strength coach, or a clinical-exercise professional working with your prescriber. What the evidence supports at the editorial-framing level is that loading needs to be progressive, that the major muscle groups should be addressed across the training week, and that the protocol should be sustainable across the entire weight-loss phase rather than concentrated into a short block at the start.
The peptide-research-tier intersection
This is the section that needs the heaviest editorial discipline, and we are going to write it within the rules we apply to every research-peptide piece on this site. Nothing in this section is a human-use protocol. Nothing in this section is a recommendation. The peptides described below are sold in the UK research-chemical market for research use only. They are not approved for human therapeutic use in the UK by the MHRA. We are describing what the published literature says about them in the body-composition research context, because the question is asked, and editorial silence does not serve the reader. It does not serve the reader if we pretend the conversation does not exist either.
AOD-9604 is a fragment of the human growth hormone molecule, the carboxy-terminal sequence, originally investigated by Heffernan and colleagues 2001 (PMID 11168838) for its lipolytic activity in animal models without the growth-promoting effects of the full hormone. The published human-trial evidence is limited and dated, and the molecule did not progress to therapeutic approval in any major regulator. It is sold in the UK and international research-chemical market and is the subject of significant online discussion in the body-composition community, which significantly exceeds what the published literature actually supports. The literature supports an investigative interest. It does not support the marketing claims made for it in the consumer space.
MOTS-c is a mitochondrial-derived peptide, sixteen amino acids long, encoded within the mitochondrial 12S ribosomal RNA gene. The Lee and colleagues 2015 paper (PMID 25738459) is the canonical introduction, identifying MOTS-c as a regulator of insulin sensitivity and metabolic homeostasis in mouse models. Subsequent work has explored its role in exercise-mimicking pathways and AMPK signalling. The body-composition relevance in the research literature is mechanistic and preclinical. There is not a published human body-recomposition trial of MOTS-c in 2026. It is a molecule of significant academic interest in mitochondrial-metabolism research. It is not a clinical lean-mass-preservation intervention.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue, originally described by Raun and colleagues 1998 (PMID 9849822), in the class of ghrelin-mimetic compounds that stimulate endogenous growth hormone release through the GHSR-1a receptor. The mechanistic interest in the body-composition context is the well-established association between endogenous growth hormone pulsatility and lean-mass maintenance across the lifespan, particularly in adults over forty-five. Ipamorelin did not progress to a therapeutic approval. It is sold in the UK research-chemical market.
We are listing these three because they are the three most frequently asked about in the body-recomposition-and-GLP-1 conversation on the UK research-peptide forums and search behaviour in 2026. We are not endorsing them. We are not describing a protocol. We are not comparing them. We are noting that they exist in the published literature, that they are sold in the research-chemical market for research use only, and that the gap between what the published literature supports and what is claimed in consumer marketing of these compounds is wide. Anyone investigating these molecules in a research context needs to do so within the legal and ethical frameworks that govern research-chemical use, and any human application is outside the scope of what this guide will discuss.
Where this hits real UK consumers
If you are a UK adult on GLP-1 medication and you have arrived at this page because you are worried about lean-mass loss, the practical landing points across this site are: the clinic directory at /clinics/ for UK GLP-1 providers and the dietitian and exercise-professional support that responsible providers integrate; the GLP-1 protein-target tool at /tools/glp1-protein-target/ if you want a general framing of where the published guidance puts the protein conversation at your body weight; the metabolic-peptides function hub at /metabolic-peptides/ for the broader editorial coverage of the research-peptide lane that this guide touched on; and the twelve-month supply cost tool at /tools/12-month-supply-cost/ for the financial planning conversation that overlaps with the multi-quarter time horizon body recomposition actually requires.
The pattern we see in UK reader behaviour on this site is that the body-recomposition question is most often asked at the three-month and the six-month mark of a GLP-1 prescription, when the rate of weight loss is at its highest and the reader has started reading the body-composition concern in the broader media coverage. That is the right window to raise the protein-and-loading conversation with your prescriber, and to ask about a baseline DXA scan if one was not already done, so that you have a measurement point to compare against later.
What we are NOT saying
We are not telling you to take any medication, to start any medication, to stop any medication, or to alter the dosing or schedule of any medication. We are not telling you to take any research peptide, to investigate any research peptide for human application, or to use any compound described in this guide on a human body. We are not telling you how much protein to eat, in kilograms, in grams, in meals, or in any other unit, for your body. We are not telling you what training to do, at what intensity, at what frequency, or in what programme structure. We are not telling you what a healthy body composition is for your body, your age, your medical history, or your goals.
What we are doing is summarising the published literature, the consensus position statements, and the editorial questions worth asking in 2026, so that the conversation with your prescriber, your dietitian, and your exercise professional is better informed when you walk into it. The decision is yours and your prescriber’s. We are an editorial layer. We are not a clinical layer. That distinction is permanent on this site, and it is permanent in this guide.
FAQ
What is body recomposition? Body recomposition is the simultaneous reduction of fat mass and preservation, or modest increase, of lean mass over a defined window. The clinical concern is that simple weight loss, without specific intervention, typically reduces both fat and lean mass at the same time, and the lean-mass loss is the component that does not easily reverse afterwards, particularly in adults over forty-five.
Why does GLP-1 medication cause lean-mass loss? The published trial data, including STEP-1 (PMID 33567185) and SURMOUNT-1 (PMID 35658024), shows that GLP-1 receptor agonist treatment produces weight loss in which a substantial proportion of the weight lost is fat-free mass rather than fat. The mechanism appears to be the same as in any large-magnitude rapid weight loss: the body adapts to the smaller energy intake by reducing all tissue compartments, not only adipose tissue. The reanalysis by Linge and colleagues (PMID 38387458) found the lean-to-fat loss ratio is broadly consistent with other weight-loss methods of equivalent magnitude.
What does the literature say about protein during weight loss? The PROT-AGE consensus (PMID 23764849) and the ESPEN position paper by Deutz and colleagues (PMID 24814383) both set protein guidance for older adults losing weight at a level meaningfully higher than the standard reference value used for sedentary adults, and recommend distributing intake across meals. The specific kilograms-per-day figure depends on baseline body weight, kidney function, and prescriber assessment, and is a conversation for a registered dietitian. The general framing is that protein intake is the single most evidence-supported lever for lean-mass preservation in this context.
Can peptides help with body recomposition? There is no published human body-recomposition trial of any research-tier peptide that meets the evidence standard the GLP-1 medications meet. AOD-9604, MOTS-c, and Ipamorelin all have published literature in adjacent mechanistic or preclinical contexts, but none are approved for human therapeutic use in the UK and none should be considered a clinical lean-mass-preservation intervention. They are sold in the UK research-chemical market for research use only. The gap between published evidence and consumer marketing claims for these compounds is wide.
What about resistance training? The general adult resistance-training literature on lean-mass preservation during weight loss is unambiguous, with the Cermak and colleagues meta-analysis (PMID 22939366) and the Morton and colleagues meta-analysis (PMID 28698222) being the canonical references. There is not yet a published gold-standard trial of GLP-1 medication with versus without a structured resistance-training arm, but the directional expectation, drawing on the adjacent literature, is that loading combined with adequate protein intake meaningfully improves the lean-to-fat loss ratio. The specific programme is a conversation for a qualified strength coach, chartered physiotherapist, or clinical-exercise professional.
What should I ask my prescriber? A short list of questions worth raising at the three-month or six-month review point on a GLP-1 prescription: whether a baseline or follow-up DXA scan is available, what protein intake your prescriber and a registered dietitian would frame at your body weight and medical history, whether a referral to a clinical-exercise professional or chartered physiotherapist is appropriate, and how lean-mass preservation strategies are being integrated into your overall treatment plan. Your prescriber is the right person to answer all of these. We are not.
Sources
PMID 33567185. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1 trial. 2021.
PMID 35658024. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1 trial. 2022.
PMID 38387458. Linge J et al. Body composition changes with GLP-1 receptor agonists: MRI-based reanalysis. 2024.
PMID 36207314. Conte C et al. Pharmacological weight loss and sarcopenia risk in older adults: narrative review. 2022.
PMID 35441470. Wilding JPH et al. Weight regain and body composition trajectory after withdrawal of semaglutide. STEP-1 extension. 2022.
PMID 34553478. Donini LM et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. 2022.
PMID 30166099. Prado CM et al. Body composition in chronic disease prognosis: review. 2018.
PMID 23764849. Bauer J et al. Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE study group. 2013.
PMID 24814383. Deutz NEP et al. Protein intake and exercise for optimal muscle function with ageing: ESPEN expert group recommendations. 2014.
PMID 22939366. Cermak NM et al. Protein supplementation augments resistance-training adaptations: meta-analysis. 2012.
PMID 28698222. Morton RW et al. Systematic review and meta-analysis of protein supplementation in resistance-trained individuals. 2018.
PMID 11168838. Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism: animal model. 2001.
PMID 25738459. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. 2015.
PMID 9849822. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. 1998.
Editorial note. This guide is informational. It is not clinical advice. It is not a recommendation for or against any medication, any research peptide, or any training or nutritional protocol. The decision about any of the topics discussed here is yours and your prescriber’s. Research peptides referenced in this guide are sold in the UK research-chemical market for research use only and are not approved for human therapeutic use by the MHRA. PeptideClear does not sell medications, does not sell research peptides, and does not provide clinical care. We are an editorial reference layer for UK adults navigating the metabolic and research-peptide landscape in 2026.